Michelle Dela Pena, APRN
Family · Naperville, ILNPI 1811518178
Payments from drug & device makers
Across 319 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$748
- Vanda Pharmaceuticals Inc.$626
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$562
- Otsuka America Pharmaceutical, Inc.$543
- Neurocrine Biosciences, Inc.$485
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,12398%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,354 |
| Johnson & Johnson | 33 | $748 |
| Vanda Pharmaceuticals Inc. | 24 | $626 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $562 |
| Otsuka America Pharmaceutical, Inc. | 19 | $543 |
| Neurocrine Biosciences, Inc. | 17 | $485 |
| Teva Pharmaceuticals USA, Inc. | 18 | $389 |
| Alkermes, Inc. | 15 | $370 |
| Lundbeck LLC | 15 | $339 |
| Axsome Therapeutics, Inc. | 13 | $319 |
| Corium, LLC | 13 | $293 |
| E.r. Squibb & Sons, L.L.C. | 13 | $274 |
| Tris Pharma Inc | 12 | $239 |
| Harmony Biosciences LLC | 4 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $113 |
| Ironshore Pharmaceuticals Inc. | 5 | $109 |
| Noven Therapeutics, LLC | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 4 | $65 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
| Neos Therapeutics, LP | 3 | $44 |
| Indivior Inc. | 2 | $37 |
| Almatica Pharma LLC | 2 | $35 |
| Orexo US, Inc. | 1 | $15 |
| USWM, LLC | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$138
- ABILIFY MAINTENA$121
- VIVITROL$103
How this compares
$7,253 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $38,497 |
| VraylarCariprazine Hcl | 21 | $38,033 |
| Aripiprazole | 37 | $3,208 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $2,171 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $1,619 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $956 |
| Bupropion XlBupropion Hcl | 32 | $908 |
| Quetiapine Fumarate | 21 | $870 |
| Fluvoxamine Maleate | 28 | $806 |
| Duloxetine Hcl | 23 | $692 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $671 |
| Clorazepate Dipotassium | 12 | $459 |
| Prazosin Hcl | 12 | $424 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 35 | $400 |
| Lamotrigine | 47 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $543 | $38,49714 claims |
| AbbVieVraylar | $1,354 | $38,03321 claims |
| Almatica Pharma LLCSertraline Hcl | $35 | $22526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Naperville
- Erin SieberNaperville$334K
- Rachel SulfridgeNaperville$13K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.